{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:23:07Z","timestamp":1791361387519,"version":"4.3.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772707"],"award-info":[{"award-number":["81772707"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273965"],"award-info":[{"award-number":["82273965"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972732"],"award-info":[{"award-number":["81972732"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M732409"],"award-info":[{"award-number":["2023M732409"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2024,7,22]]},"DOI":"10.1038\/s41416-024-02725-4","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T16:07:27Z","timestamp":1717171647000},"page":"347-360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["PDZK1 confers sensitivity to sunitinib in clear cell renal cell carcinoma by suppressing the PDGFR-\u03b2 pathway"],"prefix":"10.1038","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1902-5251","authenticated-orcid":false,"given":"Haibo","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6132-4343","authenticated-orcid":false,"given":"Yumeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0237-2379","authenticated-orcid":false,"given":"Wenxiu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuedi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duiping","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songlin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5164-802X","authenticated-orcid":false,"given":"Tao","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5921-1297","authenticated-orcid":false,"given":"Junqi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,31]]},"reference":[{"key":"2725_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin"},{"key":"2725_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.eururo.2018.08.036","volume":"75","author":"U Capitanio","year":"2019","unstructured":"Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75:74\u201384. https:\/\/doi.org\/10.1016\/j.eururo.2018.08.036.","journal-title":"Eur Urol"},{"key":"2725_CR3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41581-020-00359-2","volume":"17","author":"E Jonasch","year":"2021","unstructured":"Jonasch E, Walker CL, Rathmell WK. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nat Rev Nephrol. 2021;17:245\u201361. https:\/\/doi.org\/10.1038\/s41581-020-00359-2.","journal-title":"Nat Rev Nephrol"},{"key":"2725_CR4","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/s41591-020-1093-z","volume":"26","author":"TK Choueiri","year":"2020","unstructured":"Choueiri TK, Kaelin WG. Targeting the HIF2\u2013VEGF axis in renal cell carcinoma. Nat Med. 2020;26:1519\u201330. https:\/\/doi.org\/10.1038\/s41591-020-1093-z.","journal-title":"Nat Med"},{"key":"2725_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ctrv.2007.12.001","volume":"34","author":"K Gupta","year":"2008","unstructured":"Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34:193\u2013205. https:\/\/doi.org\/10.1016\/j.ctrv.2007.12.001.","journal-title":"Cancer Treat Rev"},{"key":"2725_CR6","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41571-019-0209-1","volume":"16","author":"RR Kotecha","year":"2019","unstructured":"Kotecha RR, Motzer RJ, Voss MH. Towards individualized therapy for metastatic renal cell carcinoma. Nat Rev Clin Oncol. 2019;16:621\u201333.","journal-title":"Nat Rev Clin Oncol"},{"key":"2725_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1177\/1758834012443725","volume":"4","author":"YG Najjar","year":"2012","unstructured":"Najjar YG, Rini BI. Novel agents in renal carcinoma: a reality check. Ther Adv Med Oncol. 2012;4:183\u201394. https:\/\/doi.org\/10.1177\/1758834012443725.","journal-title":"Ther Adv Med Oncol"},{"key":"2725_CR8","doi-asserted-by":"publisher","first-page":"x25","DOI":"10.1093\/annonc\/mdm411","volume":"18","author":"S Oudard","year":"2007","unstructured":"Oudard S, George D, Medioni J, Motzer R. Treatment options in renal cell carcinoma: past, present and future. Ann Oncol. 2007;18:x25\u201331. https:\/\/doi.org\/10.1093\/annonc\/mdm411.","journal-title":"Ann Oncol"},{"key":"2725_CR9","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1200\/JCO.22.00868","volume":"40","author":"WK Rathmell","year":"2022","unstructured":"Rathmell WK, Rumble RB, Van Veldhuizen PJ, Al-Ahmadie H, Emamekhoo H, Hauke RJ, et al. Management of metastatic clear cell renal cell carcinoma: ASCO guideline. J Clin Oncol. 2022;40:2957\u201395. https:\/\/doi.org\/10.1200\/JCO.22.00868.","journal-title":"J Clin Oncol"},{"key":"2725_CR10","doi-asserted-by":"publisher","unstructured":"Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3. https:\/\/doi.org\/10.1038\/nrdp.2017.9.","DOI":"10.1038\/nrdp.2017.9"},{"key":"2725_CR11","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/nrneph.2017.82","volume":"13","author":"EM Posadas","year":"2017","unstructured":"Posadas EM, Limvorasak S, Figlin RA. Targeted therapies for renal cell carcinoma. Nat Rev Nephrol. 2017;13:496\u2013511. https:\/\/doi.org\/10.1038\/nrneph.2017.82.","journal-title":"Nat Rev Nephrol"},{"key":"2725_CR12","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","volume":"20","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Rini BI, McDermott DF, Ar\u00e9n Frontera O, Hammers HJ, Carducci MA, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019;20:1370\u201385. https:\/\/doi.org\/10.1016\/S1470-2045(19)30413-9.","journal-title":"Lancet Oncol"},{"key":"2725_CR13","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.eururo.2021.06.009","volume":"80","author":"A M\u00e9jean","year":"2021","unstructured":"M\u00e9jean A, Ravaud A, Thezenas S, Chevreau C, Bensalah K, Geoffrois L, et al. Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy? Eur Urol. 2021;80:417\u201324. https:\/\/doi.org\/10.1016\/j.eururo.2021.06.009.","journal-title":"Eur Urol"},{"key":"2725_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15586\/jkcvhl.2014.7","volume":"1","author":"C Morais","year":"2014","unstructured":"Morais C. Sunitinib resistance in renal cell carcinoma. J Kidney Cancer Vhl. 2014;1:1\u201311.","journal-title":"J Kidney Cancer Vhl"},{"key":"2725_CR15","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00432-013-1510-5","volume":"139","author":"G Dranitsaris","year":"2013","unstructured":"Dranitsaris G, Schmitz S, Broom RJ. Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy. J Cancer Res Clin Oncol. 2013;139:1917\u201326. https:\/\/doi.org\/10.1007\/s00432-013-1510-5.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2725_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1634\/theoncologist.2011-S2-32","volume":"16","author":"A Ravaud","year":"2011","unstructured":"Ravaud A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. The Oncologist. 2011;16:32\u201344. https:\/\/doi.org\/10.1634\/theoncologist.2011-S2-32.","journal-title":"The Oncologist"},{"key":"2725_CR17","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1093\/annonc\/mdv315","volume":"26","author":"S Bracarda","year":"2015","unstructured":"Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, et al. Sunitinib administered on 2\/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Ann Oncol. 2015;26:2107\u201313. https:\/\/doi.org\/10.1093\/annonc\/mdv315.","journal-title":"Ann Oncol"},{"key":"2725_CR18","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.critrevonc.2013.09.002","volume":"89","author":"S Bracarda","year":"2014","unstructured":"Bracarda S, Sisani M, Marrocolo F, Hamzaj A, Del Buono S, De Simone V. GOAL: an inverse toxicity-related algorithm for daily clinical practice decision making in advanced kidney cancer. Crit Rev Oncol Hematol. 2014;89:386\u201393. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.09.002.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2725_CR19","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1093\/annonc\/mdx075","volume":"28","author":"JJ Knox","year":"2017","unstructured":"Knox JJ, Barrios CH, Kim TM, Cosgriff T, Srimuninnimit V, Pittman K, et al. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Ann Oncol. 2017;28:1339\u201345. https:\/\/doi.org\/10.1093\/annonc\/mdx075.","journal-title":"Ann Oncol"},{"key":"2725_CR20","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00280-019-03935-x","volume":"84","author":"Y Yamada","year":"2019","unstructured":"Yamada Y, Ohno Y, Kato Y, Kobayashi R, Hayashi H, Miyahara S, et al. Optimal dose of sunitinib for long-term treatment in Japanese patients with renal cell carcinoma. Cancer Chemother Pharmacol. 2019;84:987\u201392. https:\/\/doi.org\/10.1007\/s00280-019-03935-x.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2725_CR21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/FTD.0000000000000663","volume":"42","author":"R Demlova","year":"2020","unstructured":"Demlova R, Turjap M, Pes O, Kostolanska K, Jurica J. Therapeutic drug monitoring of sunitinib in gastrointestinal stromal tumors and metastatic renal cell carcinoma in adults\u2014a review. Ther Drug Monit. 2020;42:20\u201332. https:\/\/doi.org\/10.1097\/FTD.0000000000000663.","journal-title":"Ther Drug Monit"},{"key":"2725_CR22","doi-asserted-by":"publisher","unstructured":"Jiao Q, Bi L, Ren Y, Song S, Wang Q, Wang Y. Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Mol Cancer. 2018;17. https:\/\/doi.org\/10.1186\/s12943-018-0801-5.","DOI":"10.1186\/s12943-018-0801-5"},{"key":"2725_CR23","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.tips.2016.08.003","volume":"37","author":"C Neul","year":"2016","unstructured":"Neul C, Schaeffeler E, Sparreboom A, Laufer S, Schwab M, Nies AT. Impact of membrane drug transporters on resistance to small-molecule tyrosine kinase inhibitors. Trends Pharmacol Sci. 2016;37:904\u201332. https:\/\/doi.org\/10.1016\/j.tips.2016.08.003.","journal-title":"Trends Pharmacol Sci"},{"key":"2725_CR24","doi-asserted-by":"publisher","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","volume":"29","author":"D Westover","year":"2018","unstructured":"Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018;29:i10\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdx703.","journal-title":"Ann Oncol"},{"key":"2725_CR25","doi-asserted-by":"publisher","unstructured":"Sekino Y, Teishima J, Liang G, Hinata N. Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma. Int J Urol. 2022. https:\/\/doi.org\/10.1111\/iju.15042.","DOI":"10.1111\/iju.15042"},{"key":"2725_CR26","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.1038\/onc.2017.199","volume":"36","author":"T Tao","year":"2017","unstructured":"Tao T, Yang X, Zheng J, Feng D, Qin Q, Shi X, et al. PDZK1 inhibits the development and progression of renal cell carcinoma by suppression of SHP-1 phosphorylation. Oncogene. 2017;36:6119\u201331. https:\/\/doi.org\/10.1038\/onc.2017.199.","journal-title":"Oncogene"},{"key":"2725_CR27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.canlet.2019.03.043","volume":"453","author":"C Zhao","year":"2019","unstructured":"Zhao C, Tao T, Yang L, Qin Q, Wang Y, Liu H, et al. Loss of PDZK1 expression activates PI3K\/AKT signaling via PTEN phosphorylation in gastric cancer. Cancer Lett. 2019;453:107\u201321. https:\/\/doi.org\/10.1016\/j.canlet.2019.03.043.","journal-title":"Cancer Lett"},{"key":"2725_CR28","doi-asserted-by":"publisher","unstructured":"Wang H, Yang W, Qin Q, Yang X, Yang Y, Liu H, et al. E3 ubiquitin ligase MAGI3 degrades c-Myc and acts as a predictor for chemotherapy response in colorectal cancer. Mol Cancer. 2022;21. https:\/\/doi.org\/10.1186\/s12943-022-01622-9.","DOI":"10.1186\/s12943-022-01622-9"},{"key":"2725_CR29","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1038\/cr.2010.111","volume":"20","author":"LH Dong","year":"2010","unstructured":"Dong LH, Wen JK, Miao SB, Jia Z, Hu HJ, Sun RH, et al. Baicalin inhibits PDGF-BB-stimulated vascular smooth muscle cell proliferation through suppressing PDGFRbeta-ERK signaling and increase in p27 accumulation and prevents injury-induced neointimal hyperplasia. Cell Res. 2010;20:1252\u201362. https:\/\/doi.org\/10.1038\/cr.2010.111.","journal-title":"Cell Res"},{"key":"2725_CR30","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nm.2575","volume":"18","author":"Y Xue","year":"2012","unstructured":"Xue Y, Lim S, Yang Y, Wang Z, Jensen LDE, Hedlund E, et al. PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. Nat Med. 2012;18:100\u201310. https:\/\/doi.org\/10.1038\/nm.2575.","journal-title":"Nat Med"},{"key":"2725_CR31","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1007\/s00432-015-2019-x","volume":"141","author":"M Shim","year":"2015","unstructured":"Shim M, Song C, Park S, Choi S, Cho YM, Kim C, et al. Prognostic significance of platelet-derived growth factor receptor-\u03b2 expression in localized clear cell renal cell carcinoma. J Cancer Res Clin Oncol. 2015;141:2213\u201320. https:\/\/doi.org\/10.1007\/s00432-015-2019-x.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2725_CR32","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/01.cad.0000361534.44052.c5","volume":"21","author":"A Carrato Mena","year":"2010","unstructured":"Carrato Mena A, Grande Pulido E, Guill\u00e9n-Ponce C. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anticancer Drugs. 2010;21:S3\u201311. https:\/\/doi.org\/10.1097\/01.cad.0000361534.44052.c5.","journal-title":"Anticancer Drugs"},{"key":"2725_CR33","doi-asserted-by":"publisher","first-page":"4404","DOI":"10.1038\/s41388-020-1297-1","volume":"39","author":"Y Qi","year":"2020","unstructured":"Qi Y, Ma Y, Peng Z, Wang L, Li L, Tang Y, et al. Long noncoding RNA PENG upregulates PDZK1 expression by sponging miR-15b to suppress clear cell renal cell carcinoma cell proliferation. Oncogene. 2020;39:4404\u201320. https:\/\/doi.org\/10.1038\/s41388-020-1297-1.","journal-title":"Oncogene"},{"key":"2725_CR34","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.7150\/jca.31676","volume":"10","author":"L Lu","year":"2019","unstructured":"Lu L, Li Y, Wen H, Feng C. Overexpression of miR-15b promotes resistance to sunitinib in renal cell carcinoma. J Cancer. 2019;10:3389\u201396. https:\/\/doi.org\/10.7150\/jca.31676.","journal-title":"J Cancer"},{"key":"2725_CR35","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/j.1365-2133.2009.09290.x","volume":"161","author":"WJ Lee","year":"2009","unstructured":"Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol. 2009;161:1045\u201351. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09290.x.","journal-title":"Br J Dermatol"},{"key":"2725_CR36","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1161\/HYPERTENSIONAHA.115.05435","volume":"66","author":"S Lankhorst","year":"2015","unstructured":"Lankhorst S, Baelde HJ, Kappers MHW, Smedts FMM, Hansen A, Clahsen-van Groningen MC, et al. Greater sensitivity of blood pressure than renal toxicity to tyrosine kinase receptor inhibition with sunitinib. Hypertension. 2015;66:543\u20139. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.115.05435.","journal-title":"Hypertension"},{"key":"2725_CR37","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1158\/1078-0432.CCR-16-2869","volume":"23","author":"V Narayan","year":"2017","unstructured":"Narayan V, Keefe S, Haas N, Wang L, Puzanov I, Putt M, et al. Prospective evaluation of sunitinib-induced cardiotoxicity in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2017;23:3601\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2869.","journal-title":"Clin Cancer Res"},{"key":"2725_CR38","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/13543784.2019.1559296","volume":"28","author":"L Stitzlein","year":"2019","unstructured":"Stitzlein L, Rao P, Dudley R. Emerging oral VEGF inhibitors for the treatment of renal cell carcinoma. Expert Opin Investig Drugs. 2019;28:121\u201330. https:\/\/doi.org\/10.1080\/13543784.2019.1559296.","journal-title":"Expert Opin Investig Drugs"},{"key":"2725_CR39","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s40265-020-01327-7","volume":"80","author":"L Hirsch","year":"2020","unstructured":"Hirsch L, Flippot R, Escudier B, Albiges L. Immunomodulatory roles of VEGF pathway inhibitors in renal cell carcinoma. Drugs. 2020;80:1169\u201381. https:\/\/doi.org\/10.1007\/s40265-020-01327-7.","journal-title":"Drugs"},{"key":"2725_CR40","first-page":"7681","volume":"7","author":"SH Song","year":"2014","unstructured":"Song SH, Jeong IG, You D, Hong JH, Hong B, Song C, et al. VEGF\/VEGFR2 and PDGF-B\/PDGFR-beta expression in non-metastatic renal cell carcinoma: a retrospective study in 1,091 consecutive patients. Int J Clin Exp Pathol. 2014;7:7681\u20139.","journal-title":"Int J Clin Exp Pathol"},{"key":"2725_CR41","doi-asserted-by":"publisher","first-page":"17050","DOI":"10.1074\/jbc.273.27.17050","volume":"273","author":"RM Baxter","year":"1998","unstructured":"Baxter RM, Secrist JP, Vaillancourt RR, Kazlauskas A. Full activation of the platelet-derived growth factor beta-receptor kinase involves multiple events. J Biol Chem. 1998;273:17050\u20135. https:\/\/doi.org\/10.1074\/jbc.273.27.17050.","journal-title":"J Biol Chem"},{"key":"2725_CR42","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1091\/mbc.2.6.413","volume":"2","author":"A Kazlauskas","year":"1991","unstructured":"Kazlauskas A, Durden DL, Cooper JA. Functions of the major tyrosine phosphorylation site of the PDGF receptor \u03b2 subunit. Cell Regul. 1991;2:413\u201325.","journal-title":"Cell Regul"},{"key":"2725_CR43","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1006\/excr.2001.5169","volume":"265","author":"ME Nickas","year":"2001","unstructured":"Nickas ME, Bernard A, Kazlauskas A. The requirement of tyrosines 579 and 581 for maximal ligand-dependent activation of the \u03b2PDGFR is influenced by noncytoplasmic regions of the receptor. Exp Cell Res. 2001;265:80\u20139. https:\/\/doi.org\/10.1006\/excr.2001.5169.","journal-title":"Exp Cell Res"},{"key":"2725_CR44","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1091\/mbc.E11-04-0374","volume":"22","author":"EC Turner","year":"2011","unstructured":"Turner EC, Mulvaney EP, Reid HM, Kinsella BT. Interaction of the human prostacyclin receptor with the PDZ adapter protein PDZK1: role in endothelial cell migration and angiogenesis. Mol Biol Cell. 2011;22:2664\u201379. https:\/\/doi.org\/10.1091\/mbc.E11-04-0374.","journal-title":"Mol Biol Cell"},{"key":"2725_CR45","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1161\/CIRCRESAHA.107.159079","volume":"102","author":"W Zhu","year":"2008","unstructured":"Zhu W, Saddar S, Seetharam D, Chambliss KL, Longoria C, Silver DL, et al. The scavenger receptor class B type I adaptor protein PDZK1 maintains endothelial monolayer integrity. Circ Res. 2008;102:480\u20137. https:\/\/doi.org\/10.1161\/CIRCRESAHA.107.159079.","journal-title":"Circ Res"},{"key":"2725_CR46","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.canlet.2009.01.027","volume":"279","author":"C Dai","year":"2009","unstructured":"Dai C, Liang Y, Wang Y, Tiwari AK, Yan Y, Wang F, et al. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett. 2009;279:74\u201383. https:\/\/doi.org\/10.1016\/j.canlet.2009.01.027.","journal-title":"Cancer Lett"},{"key":"2725_CR47","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1124\/dmd.108.024612","volume":"37","author":"S Shukla","year":"2009","unstructured":"Shukla S, Robey RW, Bates SE, Ambudkar SV. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos. 2009;37:359\u201365. https:\/\/doi.org\/10.1124\/dmd.108.024612.","journal-title":"Drug Metab Dispos"},{"key":"2725_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100929","volume":"67","author":"J Jin","year":"2023","unstructured":"Jin J, Xie Y, Zhang JS, Wang JQ, Dai SJ, He WF, et al. Sunitinib resistance in renal cell carcinoma: from molecular mechanisms to predictive biomarkers. Drug Resist Updat. 2023;67:100929. https:\/\/doi.org\/10.1016\/j.drup.2023.100929.","journal-title":"Drug Resist Updat"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02725-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02725-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02725-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T13:03:08Z","timestamp":1721653388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02725-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,7,22]]}},"alternative-id":["2725"],"URL":"https:\/\/doi.org\/10.1038\/s41416-024-02725-4","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,31]]},"assertion":[{"value":"11 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Animal experiments were conducted in compliance with the National Institutes of Health guidelines for the Care and Use of Laboratory Animals and approved by the Animal Use and Care Committee of Capital Medical University (approval numbers AEEI-2020-133 and AEEI-2018-201). The research involving ccRCC samples was approved by the Ethics Committee of Capital Medical University (2017SY09) and the First Hospital of Shanxi Medical University (2022HLL001).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from all patients for the use of their tissue specimens and publication of this report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}